1Kumar R,Angelini S,Czene K,et al.BRAF mutations in meta-static melanoma:apossible association with clinical outcome[J].Clin Cancer Res,2003,9:3362.
2Balmanno K,Cook SJ.Tumour cell survival signalling by theERK1/2pathway[J].Cell Death Differ,2009,16:368.
3Wickenden JA,Jin H,Johnson M,et al.Colorectal cancer cellswith the BRAF(V600E)mutation are addicted to the ERK1/2pathway for growth factor-independent survival and repression ofBIM[J].Oncogene,2008,27:7150.
4Amado R G,Wolf M,Peeters M,et al.Wild-type KRAS is re-quired for panitumumab efficacy in patients with metastatic color-ectal cancer[J].J Clin Oncol,2008,26:1626.
5Di Nicolantonio F,Martini M,Molinari F,et al.Wild-type BRAFis required for response to panitumumab or cetuximab in meta-static colorectal cancer[J].J Clin Oncol,2008,26:5705.
6Yokota T,Ura T,Shibata N,et al.BRAF mutation is a powerfulprognostic factor in advanced and recurrent colorectal cancer[J].Br J Cancer,2011,105:856.
7Domingo E,Laiho P,Ollikainen M,et al.BRAF screening as alow-cost effective strategy for simplifying HNPCC genetic testing[J].J Med Genet,2004,41:664.
8Davies H,Bignell GR,Cox C,et al.Mutations of the BRAF genein human cancer[J].Nature,2002,417:949.
